Qu Biologics.png
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
August 18, 2020 14:35 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics.png
Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection
April 06, 2020 06:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics.png
Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
December 18, 2019 17:35 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
Qu Biologics.png
First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment
November 13, 2018 06:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics.png
Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours
November 05, 2018 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics.png
Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
October 01, 2018 07:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics.png
Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team
November 08, 2017 16:29 ET | Qu Biologics
VANCOUVER, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics.png
Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)
May 23, 2017 15:30 ET | Qu Biologics
VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the...
Qu Biologics.png
Qu Biologics invited to present Research Data at International Scientific Meetings
May 03, 2017 12:47 ET | Qu Biologics
VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Innovation Grant Awarded for Qu Biologics Project with University of Ottawa Scientist
April 04, 2017 15:15 ET | Qu Biologics
VANCOUVER, British Columbia, April 04, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...